| Literature DB >> 28164130 |
Tamer Tüzüner1, Sedanur Turgut2, Ozgul Baygin1, Nagehan Yilmaz1, Elif Bahar Tuna3, Bugra Ozen4.
Abstract
Background. The chronic recommendation of pediatric drugs could exhibit erosive and cariogenic problems. Objective. To evaluate the effects of different pediatric drugs on the color stability of various restorative materials. Methods. Five specimens (1 mm × 3 mm) were prepared and immersed in ten different pediatric drugs and agitated every 8 hours daily for 2 min up to 1 week. Between immersion periods, the samples were stored in artificial saliva. After 1-week period, ΔE⁎ values were calculated. Two-way ANOVA and Fisher's LSD test were used for statistical analysis at a level of p < 0.05. Results. ΔE⁎ values were only significantly influenced by restorative material factor (p < 0.001) and varied in the range of 2.08 and 6.55 units for all drugs/restorative materials. The highest ΔE⁎ was found in Ferrosanol B-composite (6.55 ± 1.38) and the lowest one was found in Dolven-glass ionomer (2.08 ± 0.40) pairwise. The most prominent ΔE⁎ value elevations were obtained in composite material compared to the compomer and/or glass ionomers in Macrol, Ferrosanol B, and Ventolin (p < 0.001; for all) and also for other drugs (p < 0.05). Dolven exhibited significantly higher values compared to Augmentin (p = 0.021), Macrol (p = 0.018), and Ventolin (p = 0.013) in compomer group. Conclusion. The clinically perceptible color changes for tested composite/pediatric drug pairwise can be more problematic than compomer and glass ionomers in pediatric dentistry.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28164130 PMCID: PMC5259657 DOI: 10.1155/2017/9684193
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Pediatric liquid drugs (PLDs) used in the study.
| PLDs | Generic name | Brand name |
|---|---|---|
| Antibiotics | Amoxicillin + clavulanic acid clarithromycin cephalosporins | Augmentin |
| Analgesics | Paracetamol | Calpol |
| Antiepileptics | Levetiracetam | Keppra |
| Multivitamins | Multivitamins | Ferrosanol B |
| Bronchodilator | Salbutamol | Ventolin |
| Anxiolytic | Hydroxyzine HCL | Atarax |
| Sympathomimetic | Pseudoephedrine HCL | Sudafed |
Restorative materials used in the study.
| Product | Material type | Mixing | Curing | Manufacturer |
|---|---|---|---|---|
| Dyract XP | Polyacid modified composite resin | N/A | Light-cure for 20 seconds | Dentsply DeTrey, GmbH, Germany |
| Nova Compo-B Plus | Composite resin | N/A | Light-cure for 20 seconds | Imicryl Dental, Konya, Turkey |
| EQUIA | Glass ionomer cement | 10 seconds with a mixer | Light-cure for 90 seconds | GC Corporation, Tokyo, Japan |
ΔE values of tested restorative materials with pediatric drugs (mean ± sd).
| Restorative materials | Composite | Compomer | Glass ionomer |
|---|---|---|---|
| Δ | Δ | Δ | |
| Drug/brand name | |||
| Augmentin | 5.9 ± 2.12a | 2.29 ± 0.92B,b | 3.82 ± 1.61c |
| Macrol | 5.63 ± 2.01a | 2.23 ± 1.98C,b | 2.34 ± 0.81b |
| Cefaks | 6.40 ± 2.2a | 4.67 ± 1.3c | 2.4 ± 0.81b |
| Calpol 6 plus | 6.64 ± 0.68a | 3.90 ± 3.01b | 2.57 ± 0.92c |
| Dolven | 5.30 ± 1.45b | 4.76 ± 3.41A,c | 2.08 ± 0.40a |
| Keppra | 5.68 ± 1.59a | 3.18 ± 1.56b | 2.72 ± 0.56c |
| Ferrosanol B | 6.55 ± 1.38a | 2.61 ± 2.03b | 2.17 ± 0.69b |
| Ventolin | 6.30 ± 1.76a | 2.09 ± 1.2D,b | 2.09 ± 0.48b |
| Atarax | 4.14 ± 1.06 | 3.1 ± 2.46 | 2.41 ± 1.02 |
| Sudafed | 6.07 ± 1.84a | 3.51 ± 2.34b | 3.13 ± 1.13c |
Significant differences were only found in compomer group between pediatric drug comparisons (pA-B = 0.021; pA–C = 0.018; pA–D = 0.013); no differences were obtained in other pairwise comparisons p > 0.05.
Significant differences were found in Augmentin group; composite-compomer (pa-b = 0.01) and composite-glass ionomer cement (pa–c = 0.04), in Macrol group; between composite-compomer/glass ionomer (pa-b = 0.002), in Cefaks group; composite-glass ionomer cement (pa-b = 0.01) and compomer-glass ionomer cement (pb-c = 0.033) in Calpol 6 plus group; between composite-compomer (pa-b = 0.011) and composite-glass ionomer (pa–c < 0.001), in Dolven group; between glass ionomer-composite (pa-b = 0.003) and glass ionomer-compomer (pa–c = 0.013), in Keppra group; composite-compomer (pa-b = 0.02) and composite-glass ionomer cement (pa–c = 0.006), in Ferrosanol B group; between composite- compomer/glass ionomer (pa-b < 0.001) in Ventolin group; between composite-compomer/glass ionomer (pa-b < 0.001) in Sudafed group; composite-compomer (pa-b = 0.009) and composite-glass ionomer cement (pa–c = 0.014). No differences were found in Atarax group (p > 0.05).
Two-way ANOVA interaction effects.
| Variable | Sum of squares | df | Mean squares |
|
|
|---|---|---|---|---|---|
| Pediatric drug | 23.704 | 9 | 2.634 | 0.943 | 0.491 |
| Restorative material | 298.904 | 2 | 149.452 | 53.508 | 0.000 |
| Pediatric drug X restorative material | 55.299 | 18 | 3.072 | 1.100 | 0.361 |
| Error | 335.168 | 120 | 2.793 | ||
| Total | 3011.920 | 150 |
df: degrees of freedom.
p < 0.001; restorative material.